Answers are grounded in this paper and cite their sources.
Chronic pain remains a leading cause of disability worldwide. While the shift from a biomedical to a biopsychosocial model has reframed pain as an integrated neuro-affective experience, clinical strategies often overlook the bidirectional interaction between nociception and emotion. This narrative review was conducted using PubMed (MEDLINE), Scopus, and Web of Science (January 2000–February 2026), with supplementary searches performed in Google Scholar. Systematic reviews, meta-analyses, randomized controlled trials, cohort studies, and relevant preclinical studies addressing pain–affect intersections were prioritized. Reciprocal influences between emotion, pain, and analgesia are synthesised across neurobiological, psychological, and pharmacological domains. Shared substrates (the “pain matrix”), neurotransmitter pathways (serotonergic, noradrenergic, and opioid), and psychological modulators (pain catastrophizing and the fear-avoidance model) are discussed, with specific attention to the lateral habenula and cortical potentiation in relation to anhedonia. Mechanisms of placebo analgesia (via endogenous opioids) and nocebo hyperalgesia (via cholecystokinin) are summarized, highlighting the impact of cognitive-emotional states on pharmacodynamics. Evidence for an “affective shift” during pain chronification is outlined, and the “hidden psychopharmacology” of non-opioid analgesics is considered, including reported emotional blunting and reduced empathy associated with paracetamol (acetaminophen). The synthesis supports a multimodal therapeutic approach combining pharmacotherapy with psychotherapy and indicates that analgesics should not be assumed to be emotionally neutral during long-term pain management.
No takes yet. Share an insight, caveat, or question.
Oleshchuk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: